Paul Tunnah reviews Hedley Rees’ ‘Taming the Big Pharma Monster: by Speaking Truth to Power’, which takes pharma to task for losing its way with patients.
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.